Market Research

Report: Rapid Growth in Medical Device Innovation Continues

A recent market report indicates the medical device field is a significant area of growth in the number of new patents.

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, released its annual analysis of global patent trends today in its fourth-annual State of Innovation report. This publication tracks patent activity across 12 key technology areas using the Thomson Reuters Derwent World Patents Index® (DWPISM) database.

Key findings from the report include:

No votes yet

Tech Innovations Drive Growth in $60 Billion Drug Delivery Market

According to a recent report, new drug delivery methods are viewed by pharma firms and packaging partners as crucial growth generators.

The next generation of advanced pharmaceutical technologies could be poised to fuel remarkable growth in the $60 billion global drug delivery market, and Rainbow Biosciences—the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC)—plans to be right in the middle of the action.

No votes yet

Report: FDA Approved 30 Percent More Drugs in 2012 Than the Previous Year

According to a recent market study, the agency’s drug approvals reached a 15-year high last year.

A sharp increase in drug approvals and mergers and acquisitions combined to create a bull market for the Biotechnology Industry in 2012. The iShares NASDAQ Biotechnology Index (IBB), the SPDR S&P Biotech ETF (XBI) and the First Trust Amex Biotechnology Index ETF (FBT) have all gained over 20 percent in the past year, outperforming the broader markets by a good margin. Research Driven Investing examines investing opportunities in the Biotech Industry and provides equity research on Amgen, Inc. (NASDAQ: AMGN) and Gilead Sciences, Inc. (NASDAQ: GILD).

No votes yet

Report: Healthcare Jobs Rising Despite Industry Challenges

A recent market study suggests medical device, pharmaceutical, and biotech companies are hiring a steady stream of sales staff, despite a tough market.

The healthcare industry continues to grow, adding 45,000 jobs last December, but the medical device and pharmaceutical sectors are facing challenges - namely increasing taxes and fees - that industry representatives say are sure to slow growth. The recently implemented medical device tax, increased user fees, and pricing pressures are certainly weighing on the industry, but a new report from MedReps.com suggests the healthcare sales job market has not seen strong repercussions.

No votes yet

HealthCanal, UBM Medica Form Marketing and Distribution Partnership

The pharmaceutical packaging and healthcare information sites will provide breaking news affecting the medical community.

HealthCanal.com announced today a unique marketing and distribution partnership with UBM Medica US. HealthCanal.com provides free medical breakthrough news to the healthcare professional community.

No votes yet

Report: Sleep Apnea Diagnosis, Treatment to Increase in 2013

Research on behalf of Sleep Group Solutions indicates that demand for sleep-apnea will increase, creating opportunities for pharma and packaging firms.

Obstructive Sleep Apnea (OSA) remains one of the more common sleep disorders in America, affecting over 20 million people each night. Adversely, OSA remains undiagnosed in over 80% of those who suffer. Sleep Group Solutions (SGS), leaders in dental sleep medicine education and technology, educates dentists how to properly identify and treat Obstructive Sleep Apnea with oral appliances.

No votes yet

Affordable Care Act, Pharma Value Proposition Among Top Health Issues of 2013

A new intelligence report looks into the top 10 issues most likely to impact the medical industry and pharmaceutical firms.

As the health industry undertakes a full transition to meet requirements of the Affordable Care Act (ACA) and to prepare for a shift in market dynamics, PwC's Health Research Institute (HRI) today published its annual list of the Top Health Industry Issues for 2013.  According to PwC US, the pace is certain to quicken in 2013 with the effects of technology, consumerism, budgetary pressures and the ACA converging on a sector that represents nearly one-fifth of the economy.

Your rating: None Average: 3 (1 vote)

Medical Marijuana Companies on the Rise

An investment group advises that pharmaceutical packaging firms, investors and others could benefit from the relaxing attitudes toward medical and recreational use of the drug.

Since the Presidential election many marijuana stocks have been steadily climbing. Three companies are positioned and primed to continue this trend. These three companies are MediSwipe Inc., Cannabis Science Inc., and Medbox Inc.

Your rating: None Average: 5 (1 vote)

Report: Feds, Big Pharma Likely to Reduce Research Funding

Two Johns Hopkins faculty members predict drug developers may need to innovate to find other funding.

In a commentary to be published in the Dec. 12 issue of The Journal of the American Medical Association, two Johns Hopkins faculty members predict an ever-diminishing role for government and drug company funding of basic biomedical research and suggest scientists look to 'innovative' kinds of private investment for future resources.

Current negotiations in Washington over sequestration and the so-called 'fiscal cliff' provide an opportunity to fundamentally rethink the funding of biomedical research, they say.

No votes yet

Roche Diagnostics to Open Learning and Development Center

The facility will focus on developing new diagnostics and diabetes care technologies.

Mayor Greg Ballard today joined Roche Diagnostics President and CEO Jack Phillips as well as other Roche executives and community leaders to break ground on the company's new Learning and Development Center. The center is the first element of a $300 million site transformation investment that was announced in June 2012. The city of Indianapolis and the Indiana Economic Development Corporation offered Roche tax abatements, tax credits and training grants to support Roche's investment.

No votes yet
Syndicate content